ERBB2 and breast cancer: Our data was not in agreement with Stagni et al., who reported that ATM activation and HER2 positivity predicted the worst DFS in breast cancer patients and patients displaying ATM‐p‐negative and HER2‐positive have moderate DFS suggesting that ATM sustained tumorigenicity of HER2 in breast cancer.28